These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 17080031)

  • 21. An alternative approach to drug discovery for Alzheimer's disease dementia.
    Schubert D; Maher P
    Future Med Chem; 2012 Sep; 4(13):1681-8. PubMed ID: 22924506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment success in Alzheimer's disease.
    Gauthier S
    J Nutr Health Aging; 2006; 10(5):416. PubMed ID: 17066214
    [No Abstract]   [Full Text] [Related]  

  • 23. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease.
    Maczurek A; Hager K; Kenklies M; Sharman M; Martins R; Engel J; Carlson DA; Münch G
    Adv Drug Deliv Rev; 2008; 60(13-14):1463-70. PubMed ID: 18655815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease.
    Boissonneault V; Filali M; Lessard M; Relton J; Wong G; Rivest S
    Brain; 2009 Apr; 132(Pt 4):1078-92. PubMed ID: 19151372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Curcumin improves learning and memory ability and its neuroprotective mechanism in mice.
    Pan R; Qiu S; Lu DX; Dong J
    Chin Med J (Engl); 2008 May; 121(9):832-9. PubMed ID: 18701050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel pharmacologic approaches to the treatment of senile dementia of the Alzheimer's type (SDAT).
    Reisberg B; London E; Ferris SH; Anand R; de Leon MJ
    Psychopharmacol Bull; 1983; 19(2):220-5. PubMed ID: 6346374
    [No Abstract]   [Full Text] [Related]  

  • 27. Animal models in the drug discovery pipeline for Alzheimer's disease.
    Van Dam D; De Deyn PP
    Br J Pharmacol; 2011 Oct; 164(4):1285-300. PubMed ID: 21371009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A perspective on risks that impede development of drugs to modify the course of Alzheimer's disease: can they be reduced?
    Mohs RC
    Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S85-7. PubMed ID: 18632007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.
    Shin KY; Lee GH; Park CH; Kim HJ; Park SH; Kim S; Kim HS; Lee KS; Won BY; Lee HG; Choi JH; Suh YH
    J Neurosci Res; 2007 Aug; 85(11):2500-11. PubMed ID: 17600377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alzheimer's disease: from pathology to therapeutic approaches.
    Jakob-Roetne R; Jacobsen H
    Angew Chem Int Ed Engl; 2009; 48(17):3030-59. PubMed ID: 19330877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Why have we failed to achieve neuroprotection in Parkinson's disease?
    Olanow CW; Kieburtz K; Schapira AH
    Ann Neurol; 2008 Dec; 64 Suppl 2():S101-10. PubMed ID: 19127580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transgenic animal models of neurodegenerative diseases and their application to treatment development.
    Rockenstein E; Crews L; Masliah E
    Adv Drug Deliv Rev; 2007 Sep; 59(11):1093-102. PubMed ID: 17869376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroprotective effect of SuHeXiang Wan in Drosophila models of Alzheimer's disease.
    Hong YK; Park SH; Lee S; Hwang S; Lee MJ; Kim D; Lee JH; Han SY; Kim ST; Kim YK; Jeon S; Koo BS; Cho KS
    J Ethnopharmacol; 2011 Apr; 134(3):1028-32. PubMed ID: 21333721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents.
    Mandel S; Amit T; Bar-Am O; Youdim MB
    Prog Neurobiol; 2007 Aug; 82(6):348-60. PubMed ID: 17659826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of celecoxib- and streptozotocin-induced experimental dementia of Alzheimer's disease by pitavastatin and donepezil.
    Sharma B; Singh N; Singh M
    J Psychopharmacol; 2008 Mar; 22(2):162-71. PubMed ID: 18208924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recommendations for best practices in the treatment of Alzheimer's disease in managed care.
    Fillit HM; Doody RS; Binaso K; Crooks GM; Ferris SH; Farlow MR; Leifer B; Mills C; Minkoff N; Orland B; Reichman WE; Salloway S
    Am J Geriatr Pharmacother; 2006; 4 Suppl A():S9-S24; quiz S25-S28. PubMed ID: 17157793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurochemical substrates of human aging and dementia.
    Mohr E; Carter C; Wallin A
    Pharmacopsychiatry; 1990 Feb; 23 Suppl 2():53-5. PubMed ID: 2186413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Partnership between academia and industry for drug discovery in Alzheimer's disease.
    Ivinson AJ; Lane R; May PC; Hosford DA; Carrillo MC; Siemers ER
    Alzheimers Dement; 2008 Mar; 4(2):80-8. PubMed ID: 18631952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hydergine helpful for Alzheimer's disease.
    Geriatrics; 1979 Oct; 34(10):23. PubMed ID: 478308
    [No Abstract]   [Full Text] [Related]  

  • 40. Animal models of Alzheimer's disease and drug development.
    Laurijssens B; Aujard F; Rahman A
    Drug Discov Today Technol; 2013 Sep; 10(3):e319-27. PubMed ID: 24050129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.